Expression of matrix metalloproteinases in human transitional cell carcinoma of the urinary bladder

Oncology Reports

Volumn 10, Issue 2, 2003, Pages 345-349

  Sumi, Toshiyuki ^a   Yoshida, Hiroyuki ^a   Hyun, Yoji ^a   Yasui, Tomoyo ^a   Matsumoto, Yoshinari ^a   Hattori, Kanae ^a   Sugimura, Kazunobu ^a   Kawashima, Hidenori ^a   Nakatani, Tatsuya ^a   Ishiko, Osamu ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Matrix metalloproteinase 2; Matrix metalloproteinase 7; Transitional cell carcinoma; Urinary bladder

Indexed keywords

GELATINASE A; MATRILYSIN;

AGED; ARTICLE; BLADDER TUMOR; CANCER INVASION; CANCER STAGING; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; ENZYMOLOGY; FEMALE; HUMAN; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TRANSITIONAL CELL CARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 18544395872     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.2.345     Document Type: Article

References (28)

1. The Japanese Urological Association and the Japanese Society of Pathology: General rules for clinical and pathological studies on bladder cancer. 2nd edition. Kanehara Press, Tokyo, 1993.
2. Abel PD, Hall RR and Williams G: Should pT1 transitional cell cancers of the bladder still be classified as superficial? Br J Urol 62: 235-239, 1988.
3. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD and Hawkins IR: Superficial bladder cancer: progression and recurrence. J Urol 130: 1083-1086, 1983. (Pubitemid 14207227)
4. Lutzeyer W, Rubben H and Dahm H: Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 127: 250-252, 1982. (Pubitemid 12131747)
5. Pauwels RP, Schapers RF, Smeets AW, Debruyne FM and Geraedts JP: Grading in superficial bladder cancer. (1). Morphological criteria. Br J Urol 61: 129-134, 1988. (Pubitemid 18067140)
6. Torti FM, Lum BL, Aston D, MacKenzie N, Faysel M, Shortliffe LD and Freiha F: Superficial bladder cancer: the primacy of grade in the development of invasive disease. J Clin Oncol 5: 125-130, 1987. (Pubitemid 17007866)
7. Kleiner DE and Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 43 (Suppl): S42-S51, 1999. (Pubitemid 29244632)
8. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991. (Pubitemid 121001258)
9. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980. (Pubitemid 10098769)
10. Nakajima M, Welch DR, Belloni PN and Nicolson GL: Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res 47: 4849-4876, 1987.
11. Sreenath T, Matrisian LM, Stetler-Stevenson W, Gattoni-Celli S and Pozzatti RO: Expression of matrix metalloproteinase genes in transformed rat cell lines of high and low metastatic potential. Cancer Res 52: 4942-4947, 1992.
12. Wilson CL and Matrisian LM: Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J BiochemCell Biol 28: 123-136, 1996. (Pubitemid 26072499)
13. Wilson CL and Matrisian LM: Matrilysin. In: Matrix Metalloproteinase. Parks WC and Mecham RP (eds). Academic Press, San Diego, pp149-184, 1998.
14. Powell WC, Knox JD, Navre M, Grogan TM, Kittelson J, Nagle RB and Bowden GT: Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 53: 417-422, 1993. (Pubitemid 23031858)
15. Witty JP, McDonnell S, Newell KJ, Cannon P, Navre M, Tressler RJ and Matrisian LM: Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res 54: 4805-4812, 1994. (Pubitemid 24276516)
16. Senota A, Itoh F, Yamamoto H, Adachi Y, Hinoda Y and Imai K: Relation of matrilysin messenger RNA expression with invasive activity in human gastric cancer. Clin Exp Metastasis 16: 313-321, 1998. (Pubitemid 28255526)
17. Wilson CL, Heppner KJ, Labosky PA, Hogan BL and Matrisian LM: Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 94: 1402-1407, 1997. (Pubitemid 27087863)
18. Rudolph-Owen LA, Chan R, Muller WJ and Matrisian LM: The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res 58: 5500-5506, 1998. (Pubitemid 28551137)
19. Adachi Y, Yamamoto H, Itoh F, Arimura Y, Nishi M, Endo T and Imai K: Clinicopathologic and prognostic significance of matrilysin expression at the invasive front in human colorectal cancers. Int J Cancer 95: 290-294, 2001. (Pubitemid 32847038)
20. Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, Mukaiya M, Hirata K and Imai K: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 19: 1118-1127, 2001. (Pubitemid 32176289)
21. Mitsiades N, Yu WH, Poulaki V, Tsokos M and Stamenkovic I: Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 61: 577-581, 2001. (Pubitemid 32128617)
22. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55: 237-241, 1995.
23. Lipponen PK, Eskelinen MJ, Kiviranta J and Pesonen E: Prognosis of transitional cell bladder cancer: a multivariate prognostic score for improved prediction. J Urol 146: 1535-1540, 1991.
24. Yamamoto K, Nakatani T, Sugimura K, Wada S, Ikemoto S, Kawashima H, Yoshimura R, Takemoto Y, Tsuchida K, Nishisaka N, Uchida J, Sugimoto T, Sakamoto W and Kishimoto T: Clinical results of total cystectomy for 92 patients with bladder cancer. Osaka City Med J 45: 175-190, 1999.
25. Lee CC, Yamamoto S, Morimura K, Wanibuchi H, Nishisaka N, Ikemoto S, Nakatani T, Wada S, Kishimoto T and Fukushima S: Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer 79: 780-789, 1987.
26. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A and Balkwill F: Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53: 5365-5369, 1993. (Pubitemid 23342150)
27. Kanda K, Takahashi M, Murakami Y, Kanayama H and Kagawa S: The role of the activated form of matrix metalloproteinase-2 in urothelial cancer. Br J Urol Int 86: 553-557, 2000.
28. Furukawa A, Tsuji M, Nishitani M, Kanda K, Inoue Y, Kanayama H and Kagawa S: Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in non-invasive and invasive tumors transplanted in mice with severe combined immunodeficiency. Urology 51: 849-853, 1998. (Pubitemid 28261946)